Astellas dumps Theravance's MRSA drug Vibativ

Astellas Pharma parted ways with Theravance ($THRX), ending a promotional partnership on the infection-fighter Vibativ. FDA-approved in 2009, the drug targets infections caused by resistant staph bacteria. Theravance said it is looking for a new marketing partner and working on "re-establishing" consistent supplies of the product. Report